Skip to Content

New Drug Approvals Archive - March 2014

See also: New Indications and Dosage Forms for March 2014

March 2014

Aveed (testosterone undecanoate) Intramuscular Injection - formerly Nebido

Date of Approval: March 5, 2014
Company: Endo Pharmaceuticals
Treatment for: Hypogonadism -- Male

Aveed (testosterone undecanoate) is a long-acting androgen depot injection for the treatment of male hypogonadism.

Xartemis XR (acetaminophen and oxycodone hydrochloride) Extended-Release Tablets

Date of Approval: March 11, 2014
Company: Mallinckrodt
Treatment for: Pain

Marketing Status: Discontinued

Xartemis XR (acetaminophen and oxycodone hydrochloride) is an extended-release analgesic and opioid agonist formulation for the management of moderate to severe acute pain.

Qudexy XR (topiramate) Extended-Release Capsules

Date of Approval: March 11, 2014
Company: Upsher-Smith Laboratories, Inc.
Treatment for: Seizures, Lennox-Gastaut Syndrome, Migraine Prophylaxis

Qudexy XR (topiramate) is an antiepileptic drug indicated for the treatment of partial onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut Syndrome in adults and children; and for the prophylaxis of migraine headache in adults and adolescents.

Hemangeol (propranolol hydrochloride) Oral Solution

Date of Approval: March 14, 2014
Company: Pierre Fabre Dermatologie
Treatment for: Infantile Hemangioma

Hemangeol (propranolol hydrochloride) is a pediatric beta-blocker formulation indicated for the treatment of proliferating infantile hemangioma.

Impavido (miltefosine) Capsules

Date of Approval: March 19, 2014
Company: Paladin Labs Inc.
Treatment for: Leishmaniasis

Impavido (miltefosine) is an oral alkylphosphocholine antiparasitic for the treatment of leishmaniasis.

Neuraceq (florbetaben F18) Injection

Date of Approval: March 19, 2014
Company: Piramal Imaging
Treatment for: Positron Emission Tomography Imaging

Neuraceq (florbetaben F18) is a radioactive diagnostic agent indicated for PET imaging of the brain to estimate β-amyloid neuritic plaquedensity in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.

Otezla (apremilast) Tablets

Date of Approval: March 21, 2014
Company: Celgene Corporation
Treatment for: Psoriatic Arthritis, Plaque Psoriasis, Behcet's Disease

Otezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behçet’s Disease.

Alprolix (coagulation factor IX (recombinant))

Date of Approval: March 28, 2014
Company: Biogen Idec, Inc.
Treatment for: Hemophilia B

Alprolix (coagulation factor IX (recombinant)) is a clotting factor IX therapy indicated to prevent bleeding in patients with hemophilia B.

New Drug Approvals Archive

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.